Pfizer will not proceed with regulatory approval for Lyrica (pregabalin), its GABA analogue, for Restless Legs Syndrome despite reporting positive...
For the treatment of Parkinson's disease under the following conditions: • Initial treatment as monotherapy, in order to delay the introduction of levodopa • In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations) For the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (see section 5.1)
Treatment of Parkinson's disease under the following conditions: Initial treatment as monotherapy, in order to delay the introduction of levodopa. In combination with levodopa, over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations in the therapeutic effect occur ("end of dose" or "on-off" type fluctuations) Or Ropinirole is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (see section 5.1).
ADARTREL is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (see section 5.1).
UrgoStart is a type of interactive wound dressing. Clinical trial evidence shows that using UrgoStart to treat diabetic foot ulcers increases wound healing compared with non-interactive dressings.